Skip to main content

CSL share price lifts on HY23 results | CSL Limited (ASX:CSL)

Sophia Mavridis
February 14, 2023

Biotherapeutics company, CSL Limited (ASX:CSL), reported its half year earnings today, beating forecasts, and the market has responded positively.

For the six months, CSL reported a 19% increase in revenue to US$7,183 million, as well as a 10% lift in net profit after tax before amortisation in constant currency to US$1,957 million. Citi were expecting NPAT of US$1,795 million.

CSL’s earnings were partly driven by a five-month contribution from Vifor Pharma, as well as impressive sales growth and record levels of plasma collections.

CSL have lifted its interim dividend by 2.9% to US$1.07 per share.

And management reaffirmed its guidance for FY2023 NPAT in the range of US$2.7 billion to US$2.8 billion at constant currency.

CSL’s share price has been on the rise today, currently trading 0.6% higher at AU$306.88, at the time of recording.

Reporting season: Mirvac results

Jessica Amir
February 6, 2020

Morning Bell 6 February

Jessica Amir
February 6, 2020

Morning Bell 5 February

Jessica Amir
February 5, 2020

Morning Bell 4 February

Jessica Amir
February 4, 2020

Morning Bell 3 February

Jessica Amir
February 3, 2020

January Market Overview

Jessica Amir
January 31, 2020

Morning Bell 31 January

Jessica Amir
January 31, 2020

Morning Bell 29 January

Jessica Amir
January 29, 2020

Morning Bell 28 January

Jessica Amir
January 28, 2020

Morning Bell 24 January

Paulina Peters
January 24, 2020